Table 2.
Characteristics of the patients recruited to the phase I/II trial.
| Primary registrants (n = 73) | Secondary registrants (n = 52) | |
|---|---|---|
| PS | ||
| 0 | 52 | 37 |
| 1 | 21 | 15 |
| 2 | 0 | 0 |
| Age | ||
| Median (years, range) | 48 (26–74) | 48 (26–74) |
| FIGO Stage (2008) | ||
| IB2 | 11 | 10 |
| IIA2 | 4 | 2 |
| IIB | 29 | 20 |
| IIIA | 1 | 0 |
| IIIB | 28 | 20 |
| Primary registrants (n = 71a) | Secondary registrants (n = 52) | |
| Tumor width before treatment | ||
| Median (cm, range) | 5.70 (4.30–9.20) | 5.70 (4.30–9.20) |
| Pelvic lymph node metastasis | ||
| No | 36 | 29 |
| Yes | 35 | 23 |
| Histopathology | ||
| SCC | 64 | 47 |
| Adeno | 6 | 4 |
| Adenosquamous | 1 | 1 |
| Others | 0 | 0 |
aTwo patients retracted consent and their details are unknown.
Adeno, adenocarcinoma; Adenosquamous, adenosquamous carcinoma; FIGO, International Federation of Gynecology and Obstetrics; PS, performance status; SCC, squamous cell carcinoma.